Executive Steering Committee

The Executive Steering Committee (ESC) consists of three Principal Investigators:

The Executive Steering Committee (ESC) oversees the entire group and they communicate with the Core Management, who in turn, communicate with the support group and the country-specific project teams through the Project Manager. The ESC will communicate directly with the Project Manager for their country, but major changes to protocols and projects must be documented for the ESC and both the Core Management and relevant Project Manager, must be notified.


iLEAD consists of well-established, reputable and well-governed operations. Good governance, ethics, quality and data security are ensured, valued and protected.

For donors and funders, iLEAD offers compelling value. For innovators, iLEAD offers fresh scope and game-changing potential. iLEAD’s core governance structure is detailed in the accompanying organogram.

Teams conducting studies within the iLEAD will require programmatic support and portfolio management across sites. The lead country is South Africa under the leadership of Professor Stevens with a careful governance structure to enable successful planning and interaction with country partners: Mozambique (led by Dr Jani) and Senegal (led by Professor Mboup).

Advisory Board

The advisory board consist of 12 members that have been carefully selected because of their global technical and/or strategic expertise. The Advisory Board interacts directly with the Executive Steering Committee (ESC) but new projects and protocols must be accepted by the ESC before entering the project portfolio.  The responsibilities of the Advisory Board include:

  • Advise the ESC on the broad topic of innovation
  • Provide consultative technical and clinical inputs (as per individual expertise) on iLEAD’s innovation portfolio
  • Assist the iLEAD leadership to identify emerging healthcare trends, access priorities and disease entities of concern within the African and Global contexts
  • Advise the ESC on iLEAD potential knowledge sharing opportunities and other outputs
  • Help ensure that iLEAD remains true to its innovation mandate
  • Advise on potential opportunities for expanding collaboration of iLEAD with appropriate partners

Rhythm of Business

The ESC convene on a quarterly basis, whereas the Advisory Board convene annually. Ad-hoc webinars/teleconferences are arranged between the ESC and Advisory Board if further consultation is needed for a specific project/s. From a programme management level, the Core Management host monthly update teleconferences with the Project Managers from each country. The ESC may join these meetings on an ad-hoc basis.

Legal Entity

The Wits Health Consortium (Pty) Ltd, based in South Africa, is the legal entity under which the iLEAD grant was awarded. As such, the governance structures that are in place for WHC and its employees will be applicable to the employees of iLEAD and its related third party partners. In addition, all staff and students will complete and sign confidentially agreements.


In addition to the above mentioned governance structures, matters requiring ethics oversight will be managed in-country by the following institutional review boards:

  • South Africa: University of the Witwatersrand (WITS) Human Research Ethics Committee (HREC).
  • Senegal: Research performed at IRESSEF is approved by the Senegalese National Ethics Committee and IRESSEF is in the process of establishing its own institutional ethics committee
  • Mozambique: Protocols are approved by the INS Institutional Bioethics Committee (CIBS) and then sent to the Mozambique Ministry of Health National Bioethical Committee for Health (CNBS) for approval. An administrative approval, given by the Ministry of Health, is also required and annual communication to both committees is expected.